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Abstract
Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-
release dimethyl fumarate is an orally administered drug for relapsing–remitting multiple sclerosis,
which has been associated with gastrointestinal side-effects in some patients.
Objectives: The purpose of this study was to determine if dimethyl fumarate alters the abundance and
diversity of commensal gut bacteria, and if these changes are associated with gastrointestinal side-
effects.
Methods: Thirty-six patients with relapsing–remitting multiple sclerosis received either dimethyl fuma-
rate (n¼ 27) or an injectable multiple sclerosis disease-modifying therapy (glatiramer acetate or inter-
ferons, n¼ 9) for 12weeks. Stool samples were collected at baseline, two and 12weeks. We included
165 healthy individuals as controls.
Results: At baseline, 16 microbial genera were altered in multiple sclerosis patients compared with
healthy controls. In the dimethyl fumarate-treated patients (n¼ 21) we observed a trend of reduced
Actinobacteria (p¼ 0.03, QFDR¼ 0.24) at two weeks, mainly driven by Bifidobacterium (p¼ 0.06,
QFDR¼ 0.69). At 12weeks, we observed an increased abundance of Firmicutes (p¼ 0.02,
QFDR¼ 0.09), mostly driven by Faecalibacterium (p¼ 0.01, QFDR¼ 0.48).
Conclusions: This pilot study did not detect a major effect of dimethyl fumarate on the gut microbiota
composition, but we observed a trend towards normalization of the low abundance of butyrate-
producing Faecalibacterium after 12weeks treatment. The study was underpowered to link microbiota
to gastrointestinal symptoms.
Keywords: Gastrointestinal microbiome, dimethyl fumarate, multiple sclerosis, faecalibacterium, gas-
trointestinal symptoms, clinical trial
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Introduction
Several recent studies suggest that patients with
multiple sclerosis (MS) have a distinct gut micro-
biota profile.1–3 Whether this has an impact on the
disease in terms of aetiology or disease progression
is unknown. Development of experimental allergic
encephalomyelitis (EAE) has been shown to depend
on the presence of gut microbiota.4 In addition,
transplantation of gut microbiota from untreated
MS patients to mice worsened EAE compared to
transplanted microbiota from healthy individuals,5,6
providing evidence of the gut microbiota as a disease
modifier.
Dimethyl fumarate (DMF) is an oral disease-
modifying drug used to treat adult patients with
relapsing–remitting MS (RRMS). The mechanisms
of action are not fully known but may include effects
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on different T cell subsets.7 The nrf2 antioxidant
pathway8 and membrane-bound hydroxycarboxylic
acid receptor 2 on leukocytes9 may also be implicat-
ed. Side-effects may give clues to the underlying
effect mechanisms. While there was a low frequency
of serious adverse events (AEs) in the phase 3 trials
of DMF, gastrointestinal (GI)-related AEs like
nausea, diarrhoea and upper abdominal pain were
common.10,11 GI symptoms were reported by
30% of the patients and caused 4% treatment dis-
continuation, but for the majority of patients these
issues occurred during the first 4–5weeks of treat-
ment and lasted for less than two weeks.12 The
mechanism for GI symptoms is not known. It is
therefore of importance to identify possible causes
and approaches to alleviate this problem.
DMF is a derivative of fumaric acid, a metabolic
intermediate in the citric acid cycle. In the dynamic
microbiota community of the gut, the ability of some
bacteria to metabolise fumaric acid is essential for
maintaining competitive advantage.13,14 Conversely,
it has been reported that fumaric acid possesses anti-
microbial properties.15,16 These observations suggest
that treatment with DMF may alter the microbiota
composition, potentially favouring certain pathogen-
ic bacteria that could contribute to the GI-related
AEs. To test this hypothesis, we designed a study
to analyse the microbiota abundance and diversity of
patient stool samples before and during DMF treat-
ment along with monitoring of GI side-effects.
Patients and methods
Participants
Patients 18 years old with confirmed diagnosis of
RRMS who satisfied the therapeutic indication as
described in the summary of product characteristics
(SmPC) were eligible for inclusion in the study.
Exclusion criteria were history of malignancy,
medication that potentially could affect the gut
microbiota during the last 30 days prior to study
entry (including antibiotics, teriflunomide, fingoli-
mod, natalizumab or alemtuzumab), pregnancy and
GI conditions. No patients used immunomodulatory
medications at the time of inclusion. For baseline
comparison, a panel of previously collected samples
from 165 healthy individuals with the same geo-
graphic distribution, recruited from the Norwegian
Bone Marrow Donor Registry, served as controls.
Study design
At the baseline visit, patients were screened for
eligibility and blood samples and food frequency
questionnaires (FFQs) were collected. Treatment
compliance, adverse events and blood samples
were monitored after four and 12weeks. In addition,
study participants filled out GI scoring records and
provided stool samples at baseline, at week two and
week 12. The early timepoint at week 2 was chosen
because GI side-effects from DMF occur primarily
in the first month,17 while 12weeks would capture
the majority of long-term microbiota changes.
Endpoints
The primary endpoint was change in gut microbiota
composition after treatment with DMF, described
as change in alpha diversity, beta diversity or abun-
dance of bacterial taxa on phylum, family and genus
level in subjects pre- versus post-DMF. Secondary
endpoints were relations between GI symptoms and
baseline microbial composition, changes in microbi-
al composition, changes in microbiota composition
in the DMF group compared to the injectable group,
and changes in microbial composition after resolu-
tion of GI symptoms. Exploratory endpoints were
GI symptoms and changes in blood markers, base-
line diet or baseline differences of gut microbiota
composition between MS patients and healthy
individuals.
Questionnaires
All subjects completed a validated self-administered
Norwegian FFQ before study start.18 The contribution
of each nutrient to total energy intake (EI) was
calculated and denoted as E%.19 A 15-item self-
reported validated questionnaire, the Gastrointestinal
Symptoms Rating Scale (GSRS) was used to mea-
sure GI symptoms.20 Each item was scored in seven
steps from ‘No discomfort’ to ‘Very severe discom-
fort’, corresponding to a score of 1–7, and a total
GSRS score ranging from 15–105, with a higher
score reflecting more symptoms. An increase of
two or more points (2) in GSRS was regarded as
GI symptoms.
Gut microbiota
Stool samples were collected by the patient at home
in special tubes with preservatives (PSP tubes,
Stratec), shipped to the central study laboratory
and stored at –80C. Microbial DNA were extracted
from stool samples using PSP Spin Stool DNA Kit
(Stratec Molecular GmbH) and sequenced on the
Illumina MiSeq platform, targeting the V3–V4
region of the 16 s rRNA. The sequences were ana-
lysed using QIIME v1.9.1 (see Supplementary
Material Methods). The same methods for stool
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Circulating markers
Serum levels of markers associated with gut micro-
biota alterations in other conditions were analysed
in duplicate using commercially available enzyme-
linked immunosorbent assays (ELISAs): soluble (s)
CD14, CD25, CD163 and LPS-binding protein
(LBP), all from RnD (Minneapolis, Minnesota,
USA) with intra- and inter-assay coefficients of var-
iation <10%.
Statistical analysis
Power calculations are not well developed in micro-
biota research and were not formally performed.
However, based on the assumption that 25%
would acquire GI side-effects and allowing for
some dropouts, the aim was to include 60 DMF
patients and 10 non-DMF patients.
All continuous variables are presented as median
and interquartile range (IQR). The statistical
approach included: (a) case-control study of baseline
MS samples compared with healthy individuals,
using Mann-Whitney U test on all available taxa
on genus level (n¼ 198), corrected with Benjamini
Hochberg false discovery rate (FDR); (b) for
changes in microbial abundance after intervention
with DMF or an injectable drug, the Wilcoxon
matched-pairs test was applied at phylum and
genus level, and all non-adjusted p-values <0.05
are reported, given the exploratory nature of this
pilot study. FDR is also reported for these tests.
Statistical analyses were performed in SPSS
Statistics v25.0 (IBM Corporation, Armonk, New
York, USA) and R version 3.4.1 for comparisons
of differential abundance at baseline between
patients and HCs. Graphical presentations were
made using Prism V7.0d software (GraphPad, San
Diego, California, USA).
Ethics and approvals
The study was performed according to the
Declaration of Helsinki. All participants gave writ-
ten informed consent. The study was approved by
the Norwegian Medicines Agency (EudraCT NOR-
BGT-14-10665) and the Regional Committee for
Health Research Ethics in South-Eastern Norway,




Thirty-seven RRMS patients from seven different
study sites (Supplementary Material Table 1) were
recruited between November 2015–March 2017.
Twenty-seven patients initiated treatment with
DMF and nine patients with an injectable disease-
modifying MS drug. One patient withdrew before
the study start (Table 1). Patients in the injectable
control group started on glatiramer acetate (n¼ 3),
peginterferon beta-1a (n¼ 3), interferon beta-1b
(n¼ 2) or interferon beta-1a (n¼ 1).
Microbiota profiles from 34 of 36 patients were
available for baseline analysis between MS patients
and HCs (Table 2), as two stool samples did
not meet quality criteria. At two weeks, four indi-
viduals were excluded from analysis because of
discontinuation of study drug due to an AE (n¼ 1),
loss to follow-up (n¼ 1) or missing samples (n¼ 2).
At 12weeks, five individuals were excluded from
analysis due to AEs leading to discontinuation
(n¼ 2), loss of follow-up (n¼ 1) and missing sam-
ples (n¼ 2). Thus, 21 (DMF) and nine (injectable)
patients were included in longitudinal analyses from
baseline to week 2. Correspondingly, 20 (DMF) and
nine (injectable) patients were analysed from base-
line till week 12.
Reduced Faecalibacterium in MS patients at baseline
When comparing baseline global gut microbiota
composition in MS patients and HCs, we found
minor, but significant, differences as measured by
beta diversity (weighted unifrac, adonis p-value¼
0.01, R2¼ 0.01, Supplementary Material Figure 1).
At genus level, 16 taxa had significantly different
abundance in MS patients compared to HCs
(QFDR<0.05, Supplementary Material Table 2).
Considering in total 40 different genera previously
reported to be associated with MS (Supplementary
Material Table 3), only one was confirmed in the
present data; a lower abundance in MS patients
of Faecalibacterium (QFDR¼ 0.02, Figure 1(a)).
No differences in intra-individual microbial (alpha)
diversity were observed between MS patients and
HCs (p¼ 0.91, Figure 1(b)).
GI symptoms in patients treated with DMF
GSRS scores at baseline were 19 (16–23) for the
DMF group and 23 (21–29) for the injectable
group (p¼ 0.11, Table 1). After two weeks,
12 (46%) of the patients receiving DMF experienced
a minimum of two (median 12, range 4–21) points
increase of the GSRS score (p¼ 0.04, Figure 2(a)),
predefined as on-treatment GI symptoms. After
12weeks, the worsening of GSRS score in the
DMF group was not significant compared to baseline
(p¼ 0.24). No significant increases of GI symptoms
Hospital, Norway




















Age, years (IQR) 45 (39–52) 44 (33–59) 0.91
Female gender, n (%) 19 (70.3%) 7 (77.8%) 0.75
HLA-DR*15 carrier, n (%) 11 (45.8%) 5 (55.6%) 0.62
Smoking, n (%) 2 (7.4%) 1 (11.1%) 0.87
BMI, kg/m2 (IQR) 25.2 (22.5–28) 20.5 (20.3–23.7) 0.09
Medication with PPI, n (%) 2 (7.4%) 2 (22.2%) 0.52
Previous treatment with DMT, n (%)a 6 (22.2%) 1 (11.1%) 0.64
EDSS score (IQR) 1.75 (1.38–3) 1 (0.5–2.5) 0.20
GSRS score (IQR) 19 (16–23) 23 (21–29) 0.11
Nutritional values
EI (kJ/day) 9939 (8259–12,514) 10581 (7940–12,296) 0.83
Fat E% 35.9 (33.7–39) 37 (27.7–41.15) 0.98
Proteins E% 15.1 (13.8–17.7) 18.7 (17.45–19.6) 0.01
Carbohydrates E% 43.8 (38.5–47.5) 41.2 (37–47.6) 0.51
Fibre E% 2.1 (1.9–2.7) 2.9 (2–3.4) 0.15
Sugar E% 5.7 (3.9–10.3) 4.7 (2.8–6.15) 0.19
Ethanol E% 0.5 (0–3.3) 0.4 (0.05–2.45) 0.86
BMI: body mass index; DMF: dimethyl fumarate; DMT: dimethylfumarate; EDSS: Expanded Disability Status Scale; EI: energy intake;
GSRS: Gastrointestinal Symptoms Rating Scale; HLA-DR: human leukocyte antigen-DR; IQR: interquartile range; PPI: proton pump
inhibitor.
aDMF-group (glatiramer acetate¼ 2, interferons¼ 2, teriflunomide¼ 2). Injectable group (interferons¼ 1).
(a) (b)
Figure 1. Faecalibacterium and alpha diversity in multiple sclerosis (MS) patients and healthy controls (HCs). (a) At baseline, MS patients had
reduced levels of butyrate-producing Faecalibacterium compared to HCs. (b) No differences in alpha diversity measures of the Shannon index
were observed. Mann-Whitney U-test, corrected with Benjamini Hochberg FDR.





Age, years (IQR) 47 (41–53) 46 (39–53) 0.76
Female gender, n (%) 104 (63%) 25 (74%) 0.23
Smoking, n (%) 15 (9%) 2 (6%) 0.53
BMI, kg/m2 (IQR) 25.8 (23.5–29.3) 24 (22.3–27.8) 0.04
Medication with PPI, n (%) 13 (8%) 4 (12%) 0.48
BMI: body mass index.; IQR: interquartile range.
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were observed in patients receiving injectable drugs
(Figure 2(b)).
AEs
Besides the questionnaire-based registration of
GI-related symptoms, adverse events were formally
registered (Table 4). Two patients discontinued
treatment with DMF due to AEs (lip oedema and
vomiting), one because of an MS attack and one
was lost to follow-up. All patients starting on inject-
able drugs completed the study. The total incidence
of adverse events was 56% in the DMF group and
89% in the injectable group (mostly injection site
and flu-like reactions). Overall, 27 (71%) of the AEs
were mild, 10 (26%) moderate and one severe. The
most common AEs in the DMF group were gastro-
intestinal (n¼ 9) and flushing (n¼ 5).
Gut microbiota alterations during disease-modifying
therapy
After two weeks on DMF, at phylum level we
observed a reduction of Actinobacteria (median
abundance reduced from 1.6% to 1.1%, p¼ 0.03,
Figure 3(a)) mainly driven by a reduction of
Bifidobacterium (1.1% to 0.7%, p¼ 0.06, Figure 3
(b)). After 12weeks of intervention, these changes
were reversed. After 12weeks of intervention
there was an increase in the ratio between the two
major phyla Firmicutes and Bacteroidetes (FB-ratio)
from 1.97 to 2.67 (p¼ 0.02) in patients receiving
DMF. The relative abundance of the Bacteroidetes
phylum decreased from 27% to 25% (p¼ 0.01,
Figure 3(c)) and Firmicutes increased from 57%
to 68% (p¼ 0.02, Figure 3(d)). Within the
Firmicutes phylum, changes were seen in the genus
of Faecalibacterium (3.9% to 6.9%, p¼ 0.01,
Figure 3(e)). In the injectable group, no changes
were seen at phylum level at either two weeks or
12weeks (Table 3). No changes were seen in meas-
ures of alpha diversity in either of the treatment
groups after two weeks or 12weeks (Figure 3(f)).
None of the statistical tests had a QFDR<0.05
(Table 3).
Microbial changes, GI symptoms and diet
Twelve patients experienced GI symptoms at two
weeks after initiation with DMF. Among these,
we found no significant changes in gut microbiota
composition between baseline and week 2
(Supplementary Material Table 4). Given the aim
of understanding the GI side-effects of DMF, we
performed an exploratory analysis (Supplementary
Material Table 5). DMF patients with GI symptoms
at two weeks had a lower abundance of Bacteroides
(p¼ 0.03, Figure 4(a)) at baseline and a lower abun-
dance of Dialister (p¼ 0.02, Figure 4(b)) after two
weeks compared to those without GI symptoms, but
none of these associations were robust to correction
for multiple testing. There were no significant differ-
ences in Bifidobacterium abundance at two weeks
(Figure 4(c)) or 12weeks between patients in the
DMF group with GI symptoms compared to those
without such symptoms.
Patients in the DMF group with GI symptoms after
two weeks of intervention had a higher relative
intake of ethanol (1.9 E% vs 0.3 E%, p¼ 0.01),
a lower intake of carbohydrates (40 E% vs
47 E%, p¼ 0.01) and a tendency to higher intake
of proteins (16.9 E% vs 14 E%, p¼ 0.08, Figure 5,
Supplementary Material Table 6) at baseline.
(a) (b)
Figure 2. Changes in gastrointestinal (GI) symptoms after intervention with dimethyl fumarate (DMF). A significant
increase in Gastrointestinal Symptoms Rating Scale (GSRS) score from baseline was seen in patients treated with DMF
after two weeks of treatment, but not in patients treated with an injectable drug. Wilcoxon matched pair tests including
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Concentrating on microbial phyla and food intake,
we observed a positive correlation between fibre
intake and the abundance of Firmicutes (r¼ 0.47,
p¼ 0.01) and Faecalibacterium (r¼ 0.44, p¼ 0.01)
at baseline.
Changes in circulating biomarkers during
intervention
In the DMF group, we observed a significant
increase from baseline to four and 12weeks of
the T cell activation marker sCD25 (Figure 6(a))
and the macrophage activation marker sCD163
(Figure 6(b)). No changes were seen in the microbial
translocation markers sCD14 or LBP. In the inject-
able group, after four and 12weeks there were
increased levels of sCD25 (Figure 6(c)) but not
sCD163 (Figure 6(d)), sCD14 or LBP.
In the DMF group, we found borderline significant
correlations between change in Firmicutes from
baseline to two weeks and change in sCD25 from
baseline to four weeks (r¼ –0.46, p¼ 0.04, Figure 6
(e)), and between change in Faecalibacterium
from baseline to two weeks and change in sCD163
from baseline to four weeks (r¼ –0.42, p¼ 0.06,
Figure 6(f)). There were no such correlations
between changes in bacterial phyla and circulating
biomarkers from baseline to 12weeks.
Discussion
In this study, a three-month intervention with DMF
was not associated with significant alterations in
the gut microbiota profile after FDR correction.
There was however a trend towards normalization
of the low abundance of Faecalibacterium observed
in MS patients compared to controls at baseline, and
(a) (b) (c)
(d) (e) (f)
Figure 3. Changes in bacterial phyla after intervention with dimethyl fumarate (DMF). At phylum-level, Actinobacteria (a) were reduced from
baseline to two weeks in patients treated with DMF, mainly explained by a reduction of Bifidobacterium (b). After three months of treatment with
DMF, there was an increase in the ratio between the two major phylum Bacteroidetes (c) and Firmicutes (d). Changes in Firmicutes were mostly
because of an increase of Faecalibacterium (e). No changes were seen in measures of alpha diversity with the Shannon index (f). Wilcoxon
matched pair tests including individuals with available data at both timepoints.
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also an early transient depletion of Bifidobacterium,
providing a rationale for further studies of a link
between the gut microbiota and effects and side-
effects of DMF in MS patients.
The most prominent trends in the DMF group
seemed to follow different courses. There was a
transient drop in Bifidobacterium at two weeks,
while Faecalibacterium gradually increased from
baseline to 12weeks. No comparable interventional
studies are available for other disease-modifying
MS treatments. There is, however, an increasing
interest in pharmamicrobiomics, i.e. how drugs
act on the microbiota and vice versa.21 Many
common drugs that are not considered typical anti-
biotics have anti-microbial effects,22 and some may
primarily act on the gut microbiota to influence the
host. The most prominent example, metformin in
type 2 diabetes,23 is also associated with GI side-
effects. Moreover, the observed antimicrobial
effects of DMF against some intestinal pathogens
suggest that a part of the changes observed at two
weeks could be related to drug-microbe
interactions.15,16
In a recent cross-sectional study of the gut micro-
biota in MS patients, individuals using DMF had a
higher abundance of Bacteroidetes and lower abun-
dance of Firmicutes compared to treatment-naı̈ve
MS patients.24 This differs from our findings,
which revealed a reduction of Bacteroidetes and an
increase of Firmicutes after initiation with DMF.
These conflicting results might be explained by
demographic differences, different study design or
a treatment longer than 12weeks which might
Table 4. Registered adverse events from the clinical
trial during the 12-week study period.





Any adverse events 15 (56) 8 (89)
Serious adverse events 1 (4) 1 (11)
MS relapse 1 (4) 0
Optic neuritis 0 1 (11)
Common non-serious
adverse events
Flushing 5 (19) 0
GI adverse event 9 (33) 0
Nausea 4 (15) 0
Vomiting 2 (7) 0
Abdominal pain 2 (7) 0
Obstipation 1 (4) 0
GI discomfort 1 (4) 0
Gastroenteritis 1 (4) 0
Sinusitis 2 (7) 0
Muscle pain 0 2 (22)
DMF: dimethyl fumarate; GI: gastro-intestinal; MS:
multiple sclerosis.
(a) (b) (c)
Figure 4. Differences in bacterial phyla in patients with gastrointestinal (GI) symptoms after intervention with dimethyl fumarate (DMF). DMF
patients with an increase of Gastrointestinal Symptoms Rating Scale (GSRS) score from baseline to two weeks had lower levels of Bacteroides (a)
at baseline, lower levels of Dialister (b) at two weeks and a tendency of reduced abundance of Bifidobacterium (c) at two weeks, compared to
those without an increase of GSRS score. Mann-Whitney U test.
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change the microbiota differently. Taken together,
this suggests that treatment with DMF has an
impact on the microbiome of patients with MS,
but further studies are needed to explore the changes.
Wang et al.15 demonstrated antibacterial activity of
DMF against Escherichia coli and Rumah et al.16
showed that DMF inhibited growth of Clostridium
perfringens. Since 16S rRNA-based microbiota pro-
filing generally yields genus level resolution, these
species are not well captured. In our data, the genera
Escherichia-Shigella and Clostridium, which
include the respective species, were captured in
about half of the individuals. No changes were
seen after intervention (Table 3).
The baseline microbiota profiles suggest that MS
patients have a different microbiota composition
compared to HCs. In line with previous studies,
we found no difference in intra-individual (alpha)
diversity, but modest significant differences for
global composition (beta diversity).1–3 A low abun-
dance of Faecalibacterium is observed in multiple
studies of patients treated for MS (Supplementary
Material Table 3). Faecalibacterium is a well-
known butyrate-producing bacterium which is also
reduced in inflammatory bowel disease.25 Butyrate
is a short-chain fatty acid (SCFA) produced by gut
bacteria from dietary fibre and is important as a
nutrient to the intestinal epithelium and as a regula-
tor of the mucosal immune system.26 In a recent
study of the non-obese autoimmune diabetes
model, specialised diets designed to maximise
SCFA production in the gut protected against disease
by reducing the number of autoreactive T cells and
increasing T regulatory cells.27 Mice with EAE
showed an improved clinical score both with a
high fibre diet and supplementation with SCFA.28
Taken together with our findings of a close relation-
ship between fibre intake and Faecalibacterium in
MS patients, it could be speculated that a fibre-rich
diet might be beneficial in MS.
The early and transient drop in Actinobacteria at two
weeks, driven by Bifidobacterium was in line with
the hypothesis of the present study. Unfortunately,
our study was underpowered to address whether this
observed change was associated with the reported GI
side-effects of DMF. However, a low abundance of
Bifidobacterium has been observed in many pheno-
types of chronic inflammation or GI symptoms. A
recent study suggested that probiotics per se could
influence immunity in MS patients.29 Although
faecal samples might have some limitations reflect-
ing GI symptoms from the upper GI tract, our results
provide a rationale for further studies addressing
(a) (b) (c)
Figure 5. Differences in energy intake at baseline in patients with gastrointestinal (GI) symptoms after intervention with dimethyl fumarate
(DMF). DMF patients with an increase of Gastrointestinal Symptoms Rating Scale (GSRS) score from baseline to two weeks had (a) a higher
intake of ethanol, (b) lower intake of carbohydrates and (c) higher intake of proteins at baseline, compared to those without increase of GSRS
score. Mann-Whitney U test.
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specifically whether probiotics could modify GI
symptoms in DMF-treated MS patients
To investigate possible inflammatory effects of
gut microbial changes, we evaluated serum markers
of inflammation previously associated with gut
microbiota composition.30–32 We found no relation-
ship between DMF intervention or GI symptoms
and sCD14 or LBP, suggesting that microbial trans-
location is not relevant. However, increases of
sCD163 and sCD25, which also correlated with




Figure 6. Changes in gut microbial serum biomarkers of inflammation after intervention with dimethyl fumarate (DMF). In the DMF group an
increase of gut microbial serum biomarkers of inflammation (a) sCD25 and (b) sCD163 were observed. In the injectable group an increase of (c)
sCD25 was observed, but no change in (d) sCD163. A negative correlation was observed between (e) the increase of Firmicutes after two weeks
and the increase of sCD163 after four weeks and (f) between Faecalibacterium and sCD163, i.e. patients with higher increase of Firmicutes or
Faecalibacterium after two weeks had lesser increase of the inflammatory biomarkers sCD25 or sCD163 after four weeks. Wilcoxon matched pair
tests including individuals with available data at both timepoints and Spearman rank correlation tests.
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observed after initiation of DMF. We also observed
an increase of sCD25 in the injectable group. In a
recent study, half of the studied MS patients had
a non-significant increase in sCD25 after initiation
of interferon beta.33 This suggests a short-term
increased systemic immune activation after initiation
of disease-modifying therapy, warranting further
studies.
The main limitation of this study is the small sample
size. This was largely due to a change in centrally
regulated priorities for oral immunomodulatory
drugs in the Norwegian market leading to a slow
inclusion rate. None of the statistical tests of the
longitudinal data met the significant threshold
using Benjamini Hochberg QFDR. However, due
to the exploratory approach of the study, we conse-
quently have chosen to report the uncorrected
p-values. All analyses performed were pre-
specified, but given the large number of investigated
variables in a small population, the results must be
interpreted with caution.
Around 20% of the included patients had a history
of previous treatment with disease-modifying thera-
py, which may have influenced the outcomes. Also,
most of the included patients had early-stage RRMS.
It was recently reported that patients with secondary
progressive MS have reduced expression of memory
T cells expressing the gut homing chemokine recep-
tor.34 Further studies should seek to include late-
stage MS. Dietary information was only obtained
at baseline. Although patients were instructed not
to change their diet, it is common to take DMF
with a meal containing protein and fat, which
could potentially have impacted on the microbial
composition. Likewise, we have no information on
the use of antibiotics except during and 30 days prior
to the study and can, therefore, not exclude con-
founding from use of antibiotics before that.
Moreover, FFQs were not administered to HCs,
and gender matching between MS patients was not
perfect. We can, therefore, not exclude the possibil-
ity that differences in diet or gender may have influ-
enced the cross-sectional results. Lastly, our study
was too short to link clinical outcome to alterations
in the microbiome, an investigation which would
require a different design.
In conclusion, 12weeks of treatment with DMF was
not associated with significant alterations in the gut
microbiota profile after correction for multiple com-
parisons in this pilot study. There was however a
trend towards a near-normalization of the low
abundance of butyrate-producing Faecalibacterium
seen in MS patients, and also a short-term depletion
of Bifidobacterium after initiation of DMF treat-
ment. Thus, a direct effect on the gut microbiota
might be a part of the therapeutic action of DMF.
The study was underpowered to firmly link micro-
biota changes to GI symptoms, and not designed
to assess the impact of microbiota on treatment
responses. Further clinical trials should evaluate if
alterations in microbiota are associated with treat-
ment effects, and whether microbial profiles can pre-
dict drug efficacy.
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